ライフサイエンスコーパス: hepatorenal syndrome

1 ctiveness and safety in patients with type 1 hepatorenal syndrome.

2 rolled trials done in 739 adults with type 1 hepatorenal syndrome.

3 plus octreotide with albumin for reversal of hepatorenal syndrome.

4 ompared with placebo in patients with type 1 hepatorenal syndrome.

5 , bacterial infection, and/or development of hepatorenal syndrome.

6 albumin and survival in patients with type 1 hepatorenal syndrome.

7 is useful in the management of patients with hepatorenal syndrome.

8 ut also heart failure in the pathogenesis of hepatorenal syndrome.

9 rome: type 1 hepatorenal syndrome and type 2 hepatorenal syndrome.

10 o the prevention and effective treatment for hepatorenal syndrome.

11 ewer patients receiving colchicine developed hepatorenal syndrome.

12 ompared with placebo in patients with type 1 hepatorenal syndrome.

13 serum creatinine and are more likely to have hepatorenal syndrome.

14 , ascites, encephalopathy, coagulopathy, and hepatorenal syndrome.

15 f different management strategies for type 1 hepatorenal syndrome.

16 s of IAH may also be seen in cardiorenal and hepatorenal syndromes.

17 A higher proportion of patients on NSBBs had hepatorenal syndrome (24% vs 11% in those not taking NSB

18 a (68.6 %), acute tubular necrosis (25.7 %), hepatorenal syndrome (5.7 %), respectively.

19 Extreme renal vasoconstriction characterizes hepatorenal syndrome, a functional and potentially rever

20 t study using this shunt in the treatment of hepatorenal syndrome, a trial of antibiotic prophylaxis

21 reversal of hepatorenal syndrome, relapse of hepatorenal syndrome after initial reversal, and adverse

22 Search terms included: hepatorenal syndrome; albumin; vasoconstrictor; terlipre

23 ised, time of hospitalization, and risks for hepatorenal syndrome and acute kidney injury.

24 with secondary end points of development of hepatorenal syndrome and response to therapy based on th

25 re two forms of hepatorenal syndrome: type 1 hepatorenal syndrome and type 2 hepatorenal syndrome.

26 o further decompensation (variceal bleeding, hepatorenal syndrome) and improves survival.

27 No patient developed hepatorenal syndrome, and 1-year survival of 67% was bet

28 ores and prevents the development of sepsis, hepatorenal syndrome, and hepatic encephalopathy.

29 ch as variceal bleeding, encephalopathy, and hepatorenal syndrome, and sociodemographic factors, such

30 The cumulative incidence of hepatorenal syndrome at 6 months was not significantly d

31 sin is useful in patients with cirrhosis and hepatorenal syndrome, but there are no data of its use i

32 tudied to improve outcomes for patients with hepatorenal syndrome, but trials have reported variable

33 Otherwise, hepatorenal syndrome carries a high mortality.

34 rrhotic patients with RF, in particular with hepatorenal syndrome, CLKT is preferable to LTA because

35 Recommended treatment for type 1 hepatorenal syndrome consists of albumin and vasoconstri

36 sociated with time-dependent change in eGFR, hepatorenal syndrome, dialysis requirement, hepatitis C,

37 gth of stay was associated with eGFR at OLT, hepatorenal syndrome, dialysis requirement, model for en

38 h as restless leg syndrome, sudden deafness, hepatorenal syndrome, erectile dysfunction, and so on.

39 n methods for the treatment or prevention of hepatorenal syndrome except to maintain adequate hemodyn

40 adrenaline-treated patients with reversal of hepatorenal syndrome had recurrence on discontinuation o

41 In patients with hepatorenal syndrome, hemodialysis can be used as a brid

42 The percentages of patients who developed hepatorenal syndrome, hepatic encephalopathy, or sepsis

43 rmed in case of different conditions such as hepatorenal syndrome, hepatichydrothorax, portal vein th

44 Hepatorenal syndrome, hepatocellular carcinoma, variceal

45 disposes the patient to variceal hemorrhage, hepatorenal syndrome, hepatopulmonary syndrome, and unco

46 evels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for

47 re sepsis (27% versus 9%, P = 0.003), type-1 hepatorenal syndrome (HRS) (16% versus 3%, P = 0.002), a

48 plications [hepatic encephalopathy, ascites, hepatorenal syndrome (HRS) and esophageal variceal hemor

49 Type-1 hepatorenal syndrome (HRS) is a common complication of b

50 nd albumin (triple therapy) is used to treat hepatorenal syndrome (HRS) often as a bridge to liver tr

51 Hepatorenal syndrome (HRS) type 1 is a progressive funct

52 Fourteen patients with LVDD developed hepatorenal syndrome (HRS) type 1 on follow-up.

53 e prerenal AKI), acute tubular necrosis, and hepatorenal syndrome (HRS), a functional type of prerena

54 Hepatorenal syndrome (HRS), a serious complication of ci

55 edict development of renal dysfunction (RD), hepatorenal syndrome (HRS), ACLF, and mortality.

56 s including hepatic encephalopathy, ascites, hepatorenal syndrome (HRS), and esophageal variceal hemo

57 plications [hepatic encephalopathy, ascites, hepatorenal syndrome (HRS), and esophageal variceal hemo

58 In patients with cirrhosis and hepatorenal syndrome (HRS), terlipressin has been used e

59 mia (PRA), acute tubular necrosis (ATN), and hepatorenal syndrome (HRS).

60 nally may be done for the renal diagnosis of hepatorenal syndrome (HRS).

61 Hepatorenal syndrome, HRS, is a diagnosis of exclusion.

62 Type 2 hepatorenal syndrome (HRS2) is a functional renal impair

63 The development of hepatorenal syndrome in liver cirrhosis leads to an incr

64 ients with acute liver failure (ALF) in whom hepatorenal syndrome is common.

65 avenous albumin therapy for the treatment of hepatorenal syndrome is ongoing with a growing body of r

66 Hepatorenal syndrome may improve by increasing renal blo

67 alopathy, ascites, hepatocellular carcinoma, hepatorenal syndrome, or bleeding caused by portal hyper

68 ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, or fulminant hepatic failure.

69 Secondary outcomes were reversal of hepatorenal syndrome, relapse of hepatorenal syndrome af

70 The hepatorenal syndrome represents the result of extreme va

71 The hepatorenal syndrome represents the result of extreme va

72 Hyponatremia and the hepatorenal syndrome result from water retention and ren

73 A meta-analysis was performed of hepatorenal syndrome reversal and survival in relation t

74 The pooled percentage of patients achieving hepatorenal syndrome reversal was 49.5% (95% confidence

75 significant increase of similar magnitude in hepatorenal syndrome reversal was also observed (odds ra

76 Neither survival nor hepatorenal syndrome reversal was significantly affected

77 ions, spontaneous bacterial peritonitis, and hepatorenal syndrome (RR = 0.42, 95% CI 0.26-0.69, NNT =

78 CLKT patients with hepatorenal syndrome showed significantly higher patient

79 sode and secondary prophylaxis), ascites and hepatorenal syndrome, spontaneous bacterial peritonitis

80 cations (hyponatremia, hepatic hydrothorax), hepatorenal syndrome, spontaneous bacterial peritonitis,

81 ), portal hypertensive gastropathy, ascites, hepatorenal syndrome, spontaneous bacterial peritonitis,

82 ars) with decompensated cirrhosis and type 1 hepatorenal syndrome that compared the efficacy of activ

83 Clinical studies of type 1 hepatorenal syndrome treatment with albumin and vasocons

84 Hepatorenal syndrome type 1 (HRS-1) in patients with cir

85 There are two forms of hepatorenal syndrome: type 1 hepatorenal syndrome and ty

86 included other specific liver diagnoses (eg, hepatorenal syndrome), viral hepatitis, and hepatobiliar

87 nd reversible causes of renal failure (i.e., hepatorenal syndrome), whereas combined liver and kidney

88 ect a significant difference in incidence of hepatorenal syndrome, which was less frequent in the gro

89 de (OR 26.25, 95% CI 3.07-224.21) to reverse hepatorenal syndrome, with low-quality evidence supporti